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Abstract
Purpose Following the nuclear accidents in Chernobyl and
later in Fukushima, the nuclear community has been faced
with important issues concerning how to search for and diag-
nose biological consequences of low-dose internal radiation
contamination. Although after the Chernobyl accident an in-
crease in childhood papillary thyroid cancer (PTC) was ob-
served, it is still not clear whether the molecular biology of
PTCs associated with low-dose radiation exposure differs
from that of sporadic PTC.
Methods We investigated tissue samples from 65 children/
young adults with PTC using DNA microarray (Affymetrix,
Human Genome U133 2.0 Plus) with the aim of identifying
molecular differences between radiation-induced (exposed to
Chernobyl radiation, ECR) and sporadic PTC. All participants
were resident in the same region so that confounding factors
related to genetics or environment were minimized.
Results There were small but significant differences in the
gene expression profiles between ECR and non-ECR PTC
(global test, p<0.01), with 300 differently expressed probe
sets (p<0.001) corresponding to 239 genes. Multifactorial
analysis of variance showed that besides radiation exposure
history, the BRAF mutation exhibited independent effects on
the PTC expression profile; the histological subset and patient
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age at diagnosis had negligible effects. Ten genes (PPME1,
HDAC11, SOCS7, CIC, THRA, ERBB2, PPP1R9A, HDGF,
RAD51AP1, and CDK1) from the 19 investigated with quan-
titative RT-PCR were confirmed as being associated with ra-
diation exposure in an independent, validation set of samples.
Conclusion Significant, but subtle, differences in gene ex-
pression in the post-Chernobyl PTC are associated with pre-
vious low-dose radiation exposure.
Keywords Papillary thyroid cancer . Children .Adolescents .
Radiation . Gene expression . Transcriptome
Introduction
Following the nuclear accidents in Chernobyl and 25 years
later in Fukushima, the nuclear community has been faced
with two important issues: first how to manage radiation con-
tamination, and second how to search for and diagnose bio-
logical consequences of low-dose internal radiation contami-
nation. The biological consequences of radioiodine contami-
nation after the Chernobyl accident were observed as early as
a few years after the accident when an increase in childhood
papillary thyroid carcinomas (PTCs) was demonstrated [1, 2].
Since then, approximately 5,000 thyroid cancer cases have
occurred in the contaminated regions of Belarus, Ukraine
and Russia, with a persisting increased risk of PTC develop-
ment in irradiated children [3]. Although the increase in PTC
incidence in contaminated regions is well demonstrated, it is
still not clear whether the molecular phenotype of PTCs asso-
ciated with low-dose radiation exposure differ from that of
sporadic PTC.
In small-scale molecular studies comparing radiation-
associated thyroid cancers with sporadic ones in patients of
similar age, no differences were observed in the overall fre-
quency of RET/PTC rearrangements, events crucial for the
activation of MAPK cascade [4–12], or in relation to the ra-
diation dose to the thyroid [13]. On the other hand, some
studies have shown only distinct types of RET/PTC rearrange-
ment in patients with radiation-associated and sporadic cancer
[10, 11] or a difference between radiation-induced and spo-
radic PTC using immunohistochemical, genomic and proteo-
mic approaches [14–16]. However, these results could have
been biased by many confounding factors (for review see
Maenhaut et al. [17]) since, except in one study [15], they
were not controlled for the potential impact of genetic and
environmental factors, patient age, histological variant or
stage of disease.
Such a well-balanced comparison study was not possible
until the establishment of the Chernobyl Tissue Bank (CTB).
Since 1998, the CTB (www.chernobyltissuebank.com) has
been prospectively collecting samples of thyroid tissue taken
from surgical specimens from patients aged under 19 at the
time of the Chernobyl accident and resident in the
contaminated areas of Ukraine and Russia. The prospective
nature of the collection means that it now includes patients
with thyroid cancer who were born after the radioactive
iodine released from the accident had decayed in the
environment. The results of two recent studies using
samples provided by the CTB [18, 19] on the gene
expression phenotype of PTC developing after low-dose
radiation exposure have been reported. However, differ-
ences were reported only in normal thyroid tissue [19] or
between tumour and normal tissue in relation to radiation
dose, but not as global differences [18, 20].
In contrast, this study searched for global differences in
molecular profiles in tumour tissue from patients who were
either exposed to Chernobyl radiation as children (exposed to
Chernobyl radiation, ECR) or were born after 1 January 1987
and therefore not exposed to radiation (not exposed to
Chernobyl radiation, non-ECR). Both groups resided in the
same areas so that potential confounding factors (e.g. environ-
ment) were minimized. Gene expression profiles with respect
to intrinsic potential confounding factors including age at PTC
diagnosis, mutational status and histological subtype of PTC
were also investigated. The study was performed as part of the
GENRISK-T project (EU grant FP6 36495) the aim of which
is to establish whether individual genetic factors influence the
risk of developing cancer of the thyroid after exposure to
ionizing radiation.
Materials and methods
The biological material for gene expression analysis was pro-
vided by the CTB as aliquots of total RNA from carefully
selected PTC tumour samples paired with RNA extracted
from the normal thyroid tissue of the same patient
(Supplementary Figure S1), after histopathological review of
specimens. After control for RNA and microarray quality, 65
PTC samples were analysed. All biological material was ob-
tained with the informed consent of either the patient or his/
her guardian, and following approval of this project by the
CTB’s External Review Panel. The CTB samples were sup-
plemented by 24 tumour samples (Supplementary Figure S1)
collected from Polish patients with differentiated thyroid can-
cer (DTC) born between 1 January 1987 and 1994, who were
included in the non-ECR group (only for the validation and
exon array study). All samples were taken during surgery with
the approval by local Ethics Committee and informed consent
was obtained from all patients.
3′ Oligonucleotide microarray study
The study included 33 PTC samples from the ECR group and
32 samples from the non-ECR group, all obtained from the
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CTB. In the ECR group, the patients received a mean thyroid
radiation dose of 288 mGy (range 45.4 to 4,595). In seven
patients (21 %) the radiation dose was higher than 1 Gy and
only in five (15 %) lower than 100 mGy. At the time of PTC
diagnosis, the ECR patients were slightly but significantly
older than the non-ECR patients. There were no significant
differences with respect to the histological subtype. The dis-
tribution of other factors, especially disease stage was compa-
rable between the two groups (Table 1).
Details on RNA isolation and microarray analysis are pro-
vided in the Supplementary material.
Validation qPCR study
In a validation study 19 independent samples from ECR pa-
tients from the CTB were compared with 17 samples from
non-ECR Polish patients. Since CTB did not posses additional
non-ECR tumour samples we decided to include samples
from Polish patients because of the common ethnicity of
Ukrainian and Polish children and stable iodine prophylaxis
in Poland after the Chernobyl accident that resulted in a stable
incidence of childhood DTC. The Polish patients were select-
ed to ensure their common ethnicity profile with the CTB
patients. The characteristics of the validation group are pre-
sented in Table 1.
Details of the qPCR analysis are provided in the
Supplementary material.
Validation exon array study
An additional comparison of the exon expression profiles was
performed for 27 PTC patients under the age of 26 years, 13
ECR and 14 non-ECR (Supplementary Table S1). Twenty
RNA samples were derived from PTC patients previously
included in the initial 3′ microarray study and from seven
new PTC patients of whom six were Polish born during the
period 1981 – 1992. Expression analysis of all human exons
was carried out using an Affymetrix Human Exon 1.0 ST
array.
Data analysis
The data discussed in this article have been deposited in
NCBI’s Gene Expression Omnibus [21] and are accessible
through GEO series accession number GSE35570 (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE35570).
Microarray data were normalized using the GCRMA algo-
rithm. First multidimensional scaling was performed. Then we
applied a method of our own for gene filtering based on a
comprehensive analysis of the technical accuracy of the mea-
surement of thyroid cancer and normal thyroid tissue gene
expression by oligonucleotide microarrays done on the same
samples in two independent laboratories at the Université libre
de Bruxelles, Belgium, and the Institute of Oncology in
Gliwice, Poland. Briefly, a subset of 19 Affymetrix CEL files
was analysed in both laboratories, Bruxelles and Gliwice, and
the results from the two laboratories for the same tumour and
normal tissue samples were compared. The overall correla-
tions between the results for pairs of samples from the two
laboratories were excellent (0.982 – 0.994). However, while
analysing the transcript-by-transcript correlations, we ob-
served that only a subpopulation of probe sets showed excel-
lent reproducibility. There was a trend for an increasing cor-
relation with increasing expression level and variance. After
extensive analysis of these relationships, the dataset was
subdivided into sets of probe sets according to their expression
and variance to discriminate between sets with good, accept-
able and poor correlation. Genes showing poor reproducibility
(log2 mean expression less than 5 and variance less than the
upper quartile of the variances of all probe sets) were filtered
out before the final analysis.
Genes differentially expressed between the ECR and non-
ECR groups were selected by a randomized block design with
two microarray batches. We used a noncorrected threshold of
p<0.001. A global test was applied to assess the overall sig-
nificance of the result, the Benjamini-Hochberg false discov-
ery rate (FDR) was calculated for every transcript.
Functional enrichment analysis, including the Kyoto
Encyclopaedia of Genes and Genomes database (KEGG;
www.genome.jp/kegg/) and Panther pathway software
(www.pantherdb.org/), were performed to identify metabolic
pathways and groups of genes with similar metabolic function
based on their annotation. A Bonferroni-corrected P value of
0.05 was considered statistically significant. The effects of
putative confounding factors such as age at PTC diagnosis,
presence of solid histoarchitecture, and presence of BRAF or
RET/PTC alteration, were analysed by separated three-way
analysis of variance (ANOVA) using batches as the fourth,
blocking, factor. Part of the analysis was performed using
BRB-ArrayTools developed by Dr. Richard Simon and the
BRB-ArrayTools Development Team (http://linus.nci.nih.
gov/BRB-ArrayTools.html).
Results
Differences between ECR and non-ECR papillary thyroid
cancer
The unsupervised multidimensional scaling analysis
showed no global difference in expression between
ECR and non-ECR tumours (Fig. 1). However, after
filtering out the low-reproducibility probe sets, with
stratification for two batches, 300 probe sets were dif-
ferentially expressed between ECR and non-ECR tu-
mours (noncorrected p< 0.001 with FDR for these genes
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in the range 0.5 – 8.5 %), and this difference was sig-
nificant (p < 0.01) in the global test of difference as
implemented in BRB-ArrayTools, i.e. this number of
genes was not likely to be obtained by chance. These
300 transcripts corresponded to 239 known genes
(Table 2 and Supplementary Table S2 and Fig. S2).
Table 1 Comparison of ECR and non-ECR patents included in the microarray study and in an independent qPCR validation study
Microarray study set qPCR validation set p value (microarray vs.
validation set)
ECR non-ECR p value ECR non-ECR p value ECR non-
ECR
Number 33 32 ND 19 17 ND ND ND
Female/male 23/10 26/6 NS 14/5 14/3 NS NS NS
Age at exposure (years), median (range) 2.3 (0.1 – 8.3) ND ND 2 (0.5 – 11.2) ND ND NS ND
Age at diagnosis (years), median (range) 17.7 (14.7 –
24.5)
16.3(7.7 –
21)
0.0002 19.5 (1.3 –
23.9)
17.4 (11.6 –
21.5)
0.06 0.07 0.04
Place of residence (province)
Kiev 10 (30.3 %) 12 (37.5 %) NS 7 (36 %) –b ND NS ND
Zhytomir 8 (24.2 %) 5 (15.6 %) NS 5 (26 %) ND NS ND
Chernigow 8 (24.2 %) 5 (15.6 %) NS 6 (31.5) ND NS ND
Sumy, Rovno, Chercassy, Pipriad 7 (21.2 %) 10 (32.3 %) NS 1 (5 %) ND NS ND
Histopathologya
Pure classic PTC 4 (12 %) 7 (22 %) NS 4 (21.1 %) 12 (70.6 %) ND NS ND
PTC with follicular areas 17 (52 %) 11 (33 %) NS 6 (31.6 %) 5 (29.4 %) ND NS ND
PTC with solid areas 12 (36 %) 14 (43 %) NS 8 (42 %) 0 ND ND ND
Unknown 0 0 ND 1 (5.2 %) 0 ND ND ND
Mutational status of PTC
RET/PTC
rearrangements
Positive 10 (30.3 %) 8 (25 %) NS Not available ND
Negative 19 (57.6 %) 22 (66.7 %) NS
Unknown 4 (12.1 %) 2 (6.3 %) NS
BRAF V600E mutation Positive 8 (24.2) 6 (18.8 %) NS
Negative 22 (66.7 %) 21 (65.6 %) NS
Unknown 3 (9.1 %) 5 (15.6 %) NS
Primary tumour (T stage)
1 12 (36 %) 11 (34 %) NS 3 (15.8 %) 8 (47.1 %) NS NS
2 4 (12 %) 5 (16 %) NS 4 (21.1 %) 4 (23.5 %) NS NS
3 17 (52 %) 16 (50 %) NS 11 (57.9 %) 5 (29.4 %) NS NS
Unknown 0 0 – 1 (5.2 %) 0 –
Lymph nodes (N stage)
0 14 (42 %) 14 (34 %) NS 8 (42.1 %) 6 (35.3 %) NS NS
1 19 (58 %) 18 (56 %) NS 10 (57.9 %) 11 (64.7 %) NS NS
1a 12 (36 %) 8 (25 %) NS 7 (36.9 %) 4 (23.5 %) NS NS
1b 7 (22 %) 10 (31 %) NS 3 (15.8 %) 7 (41.2 %) NS NS
Unknown 0 0 1 0
Distant metastases (M stage)
0 29 (87 %) 30 (94 %) NS 17 (89.3 %) 16 (94.1 %) NS NS
1 4 (13 %) 2 (6 %) NS 2 (10.7 %) 1 (5.9 %) NS NS
ND not determined, NS not significant
Significant p values are shown in bold
a In the ECR groups and non-ECR group in the microarray study, histopathology was evaluated according the CTB criteria as: pure classic PTC, PTC
with follicular areas (dominant pattern of follicular structures), and PTC with solid areas (dominant pattern of solid areas). In the non-ECR group from
Poland (qPCR validation study), histopathology was evaluated according to the WHO 2004 criteria
b Group from Poland
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Pathway enrichment analysis in the KEGG database
showed that genes differentially expressed between
ECR and non-ECR tumours were involved in two
endocrine-related cancer pathways (prostate and endo-
metrium), non-small-cell lung cancer and tight junction.
In the Panther pathway analysis among others the PI3
kinase pathway was involved (Supplementary Table S3).
Analysis of potential confounding factors
In-depth analysis of the potential intrinsic confounding factors
was carried out to exclude their influence on the radiation-
related differences in gene expression profile. Initially, age at
PTC diagnosis, presence of solid pathomorphology and pres-
ence of the BRAF or RET/PTC alteration known to trigger
PTC were considered for their relationship with the differ-
ences in gene expression between ECR and non-ECR tumours
by separate three-way analyses of variance (Supplementary
Table S4). No association between gene expression profile
and patient age (younger than 16 years of age vs. older) was
seen for a FDR of <10 %. BRAF mutation was significantly
associated with the PTC gene expression profile (794 probe
sets), while there were only 13 probe sets associated with
RET/PTC rearrangement with the same criteria. The differ-
ence in gene expression related to radiation exposure was also
independently significant in the presence of solid
pathomorphology. In the final analysis of putative confound-
ing factors, we includedBRAFmutation and solid PTC variant
with radiation exposure. Our analysis revealed that radiation
exposure was associated with differences in gene expression
regardless of the BRAF mutation effect (significantly associ-
ated with a number of transcripts) and of the influence of solid
PTC variant, that was negligible in multivariate analysis for a
FDR <10 % (Table 3).
Validation of the results by qPCR
To validate the low-dose irradiation-induced changes in gene
expression, we selected 19 genes from the ECR/non-ECR
gene signature for qPCR in an independent set of 36 PTC.
In the ECR group there were 19 PTC samples derived from
CTB and independent of the microarray set, and in the non-
ECR group 17 samples collected from adolescent Polish pa-
tients undergoing surgery because of PTC (Supplementary
Figure S1). Gene selection was performed based on prelimi-
nary microarray analysis (data not shown). The criterion for
selection was a significant difference in expression between
ECR and non-ECR tumours, and the biological function of the
gene (we decided to select genes involved in response to DNA
damage). The curated list of 19 genes was selected
(Supplementary Table S5) and expression of all of them was
estimated by qPCR independent from the set of PTC samples,
separate from those investigated by microarray. Of the 19
genes, 10 (52 %) were validated: PPME1 (fold changes of
1.19 and 1.25 in the ECR group in the microarray experiment
and in qPCR validation, respectively),HDAC11 (fold changes
of 1.47 and 1.25), SOCS7 (fold changes of 1.38 and 1.22),
CIC (fold changes of 1.26 and 1.22), THRA (fold changes of
1.32 and 1.16), ERBB2 (fold changes of 1.32 and 1.34),
PPP1R9A (fold changes of 1.5 and 1.23),HDGF (fold chang-
es of 1.19 and 1.28), RAD51AP1 (fold changes of 0.58 and
0.55) and CDK1 (fold changes of 0.57 and 0.67) (Fig. 2).
Genes that were not confirmed in the qPCR analysis included
MKNK2, RAS, JUB,USP15, FAM105A,MNT,GPX7, PALM3
and GNA11.
Validation by exon array
Finally, 27 PTC (13 ECR, and 14 non-ECR) were considered
for the exon expression validation analysis (in the non-ECR
group there were eight CTB samples and eight Polish sam-
ples). From the 239 genes specified by the initial gene expres-
sion microarray study, 52 (22 %) were confirmed at the level
of FDR <10 % (Table 2 and Supplementary Table S2).
Discussion
Although a rise in the incidence of thyroid cancer after the
Chernobyl accident is evident [3, 22], the question of the
potential molecular peculiarities of these induced tumours
has not yet been resolved. Answering this question is not only
of scientific interest, but also may expand our knowledge on
how to manage internal radiation contamination.
In our study of post-Chernobyl PTC, we observed small
but significant changes in the expression of 239 genes
(p<0.01) between tumours arising after exposure to low-
dose radiation after the Chernobyl accident and sporadic
Fig. 1 Multidimensional scaling of samples. Samples coloured red are
ECR tumours, green are non-ECR tumours, blue are ECR normal thy-
roids, and cyan are non-ECR normal thyroids
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PTCs. Our study is among the first to find differences in gene
expression profiles between radiation-induced and sporadic
PTC in patients matched for their ethnicity, place of residence,
sex, histopathology, disease stage and age at diagnosis. Five
previous transcriptomic studies comparing radiation-induced
and sporadic thyroid cancer [16, 23–26] were limited by the
small number of studied patients, were not matched between
sporadic and radiation-induced PTC due to differences in geo-
graphical distribution of the patients [23, 25, 26] and in PTC
stage [25], and compared expression alterations in radiation-
induced cancer with data repositories of sporadic PTC in
adults [16]. The recently published study by Abend et al.
[20] in which a well-characterized cohort of patients with
radiation-induced PTC were analysed, showed radiation
dose-dependent gene expression changes, but did not globally
compare exposed and non-exposed patients. Our results sup-
port their general conclusion on the long-term differential
gene expression in PTC arising after ionizing radiation
Table 2 Top 30 genes differentiating ECR and non-ECR papillary thyroid cancers
Gene ECR/non-ECR
expression
microarray
ECR/non-ECR
3-ANOVA
ECR/non-ECR
exon microarray
ECR/non-ECR
qPCR
Symbol Description FDR Fold
change
P value FDR FDR Fold
change
FDR Fold
change
USP27X Ubiquitin-specific peptidase 27, X-linked 0.00516 1.34 0.0000093 0.05 NS ND
ANKS6 Ankyrin repeat and sterile alpha motif domain
containing 6
0.0103 1.34 0.0000152 0.05 0.058 1.35 ND
GPX7 Glutathione peroxidase 7 0.0103 0.61 0.0000007 0.019 9 NS
MNT MAX binding protein 0.0187 1.28 0.0000031 0.04 0.058 1.22 NS
PPP1R9A Protein phosphatase 1, regulatory (inhibitor) subunit 9A 0.0341 1.5 0.0000137 0.05 NS 0.021 1.225
MKNK2 MAP kinase interacting serine/threonine kinase 2 0.0341 1.29 0.000114 0.094 0.133 1.22 NS
DDR1 Discoidin domain receptor tyrosine kinase 1 0.0341 1.34 0.000353 NS 0.070 1.33 ND
HNRNPUL2 Heterogeneous nuclear ribonucleoprotein U-like 2 0.0341 1.25 0.0000225 0.053 0.070 1.08 ND
GNL1 Guanine nucleotide binding protein-like 1 0.0341 1.23 0.000235 NS 0.101 1.12 ND
PTCD3 Pentatricopeptide repeat domain 3 0.0341 0.8 0.0000205 0.053 NS ND
ZBTB43 Zinc finger and BTB domain containing 43 0.0341 1.4 0.000068 0.09 NS ND
CIC Capicua homologue (Drosophila) 0.0341 1.26 0.0000521 0.09 NS 0.008 1.221
GMEB2 Glucocorticoid modulatory element binding protein 2 0.0341 1.26 0.000213 NS 0.070 1.18 ND
ZBTB7C Zinc finger and BTB domain containing 7C 0.0341 1.44 0.00015 NS 0.148 1.22 ND
KIAA0182 KIAA0182 0.0341 1.32 0.000311 NS 0.123 1.14 ND
GNA11 Guanine nucleotide binding protein (G protein),
alpha 11 (Gq class)
0.0341 1.25 0.000112 0.094 0.130 1.22 NS
HDAC11 Histone deacetylase 11 0.0341 1.47 0.000071 0.09 0.114 1.20 0.004 1.247
SPATA2L Spermatogenesis associated 2-like 0.0341 1.26 0.000695 NS NS ND
SLC25A23 Solute carrier family 25 (mitochondrial carrier, phosphate
carrier), member 23
0.0341 1.41 0.000126 NS 0.090 1.31 ND
TIA1 TIA1 cytotoxic granule-associated RNA binding protein 0.0341 0.73 0.0000142 0.05 NS ND
PALM3 Paralemmin-3 0.0341 3.42 0.000182 NS 0.136 1.17 NS
LYPLA2 Lysophospholipase II 0.0341 1.23 0.000138 NS NS ND
MOB2 Mps one binder kinase activator-like 2 0.0341 1.22 0.000189 NS NS ND
HDGF hepatoma-derived growth factor (high-mobility group
protein 1-like)
0.0349 1.19 0.0000155 0.05 0.070 1.13 0.021 1.275
GOPC Golgi-associated PDZ and coiled-coil motif containing 0.0359 1.36 0.0000616 0.09 NS ND
JUB Jub, ajuba homolog (Xenopus laevis) 0.0359 1.39 0.000181 NS 0.093 1.25 NS
CTBP2 C-terminal binding protein 2 0.0359 1.29 0.000171 NS NS ND
EHMT2 Euchromatic histone-lysine N-methyltransferase 2 0.0362 1.27 0.00011 0.094 0.101 1.17 ND
RAD51AP1 RAD51 associated protein 1 0.0362 0.58 0.000218 NS 0.100 0.86 0.021 0.553
SPRYD3 SPRY domain containing 3 0.0362 1.3 0.000672 NS 0.075 1.32 ND
FDR false discovery rate, ND not determined, NS not significant
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exposure. This observation is also supported by recent results
[15] demonstrating that PTC driver alterations are more prev-
alent in PTC in children who have been exposed to radiation.
Although to our knowledge our matched group of
radiation-exposed patients and patients with sporadic PTC is
optimal because of the availability of current biological
samples, we are aware of a potential drawback in the ability
to identify sporadic PTC developing in radiation-exposed pa-
tients. According to epidemiological estimation, about 29 %
of patients in our ECR group may have developed PTC in the
absence of radiation exposure [27]. The figure may possibly
be even higher if the increased identification of PTC due to
screening of the population is taken into account.We therefore
cannot rule out the inclusion of some sporadic cancers in our
ECR group. However, we were able to identify significant,
although subtle, differences in gene expression profiles be-
tween ECR and non-ECR cancers. We can speculate that the
inclusion of sporadic PTC may be one of the reasons for very
subtle difference in gene expression with a fold change in the
range 0.48 – 3.42. Also at the molecular level, in the ECR
group we failed to separate tumours clustering closer to those
in the non-ECR group either in the unsupervised multidimen-
sional scaling principle component analysis (PCA) (Fig. 1) or
in the more detailed supervised analysis. This leads us to
speculate that the different gene expression between ECR
and non-ECR tumours is rather related to radiation response
than to carcinogenesis.
Our negative findings using PCA are in line with the results
of Dom et al. [19], who in cooperation and in parallel with our
group studied gene expression in normal thyroid tissue of
radiation-exposed and non-exposed patients. They also were
not able to show any differences using PCA, and only
Table 3 The gene signature of exposure to Chernobyl radiation:
analysis of putative confounding factors. First, four different three-way
analyses were performed (with series-related subgroups) for interaction
with age at diagnosis, presence of the BRAF or RET/PTC alteration, and
solid histoarchitecture. For each of the analysed factors, the number of
genes significant at p< 0.001 is shown in Supplementary Table S4. A
final analysis performed for the three factors with the strongest effect
and two series of examinations, which included exposure to Chernobyl
radiation, BRAF mutation, and pathology (with subdivision into two
groups, one including the classic and follicular variants, and the other
both specified subgroups with solid appearance) is shown
Effect No of probe sets
at p< 0.001
No of probe sets
at FDR <10 %
Exposure to Chernobyl
radiation
196 33
BRAF mutation 183 114
Pathology (classical
and follicular/solid
component)
32 0
Fig. 2 Genes validated in the qPCR study
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significance analysis of microarrays (SAM) with adjustment
for age was able to identify 403 differentially expressed genes
in normal thyroid tissue. Similarly in our study the difference
between ECR and non-ECR tumours could only be detected
after careful quality assurance, including gene filtering ac-
cording to their expression level and variance. Thus, with such
a stringent criterion, it is not surprising that there were only a
few overlapping genes when we compared our 239 differen-
tiating genes with the results of others. None of the top 15
candidate genes found to differ between radiation-induced and
sporadic PTC by Port et al. [25] overlapped with ours or two
other sets. No overlap was found either for the ten genes
validated by us by qPCR.Only one gene (NEDD4L) identified
by Detours et al. [23], four genes (ALDH6A1, TPD52L1,
GPX1, ECE1) identified by Stein et al. [16] and two genes
(MYO1C, IGF1R) identified by Ugolin et al. [26] were ob-
served in our microarray gene signature.
Given that our multifactorial analysis of variance excluded
the contribution of age differences and tumour pathology to the
difference in gene expression profiles between the ECR group
and non-ECR group, one can hypothesize that the genes iden-
tified here reflect a true difference between non-ECR and ECR
PTC. However, our results also support an independent effect
of a BRAF mutation on PTC gene expression profile.
Interestingly, the effects of the presence of RET/PTC rearrange-
ments were smaller [28]. This is consistent with the findings of
previous studies showing differences between the effects of
BRAF and RET/PTC alterations on gene expression in thyroid
cancer [29, 30]. The frequency of RET/PTC rearrangements
was not as high, and ofBRAFmutation not as low as previously
reported in post-Chernobyl PTC [7, 8, 12, 31]. This is also
consistent with the fact that the median age of the patients at
diagnosis was 17.7 years, which is distinctly higher than in
previous post-Chernobyl cohorts [3], but similar to the age of
the patients recently reported by Sassolas et al. [32]. The rela-
tionship between age at diagnosis and frequency of BRAF and
RET/PTC alterations has also been previously identified in
Ukrainian patients [33]. The requirement to age-match the pa-
tients with patients with sporadic PTC, which is more common
in older children, in this study meant that patients in the ECR
group were also slightly older than in the previous studies that
did not use age-matched controls. In addition, 52 of our genes
were validated by exon array analysis done in the partially
independent and smaller set of tumours.
Environmental factors, such as differences in iodine defi-
ciency, also need to be taken into consideration [34]. However
in our study the place of residence of patients in the ECR and
non-ECR groups were evenly distributed within different re-
gions (oblast) and we consider that in a retrospective series
cases this is the best available method to control for differ-
ences in iodine dietary status. Unlike other authors [18, 20],
we did not show formal analysis of gene expression in relation
to individual radiation doses provided by the CTB [35].
Although the Spearman’s dose–response correlation indicated
a few significant genes (data not shown), due to uncertainty in
radiation dose and possible inclusion of patients with sporadic
PTC in the non-ECR group, we consider these data too biased.
Furthermore, recently reported studies indicate more diverse
gene expression profile with decreasing absorbed doses. This
was observed inmouse thyroid cells after injection of different
amounts of 211At or 131I radionuclides [36, 37]. It was hy-
pothesized that at high absorbed doses, the DNA lesions
might have been too complex to be properly repaired,
resulting in reduced cellular response compared to that
at lower absorbed doses.
An important feature of the investigated PTC patients was
their young age, which contributed to the different PTC gene
expression profile compared with adult patients (data not
shown). However, our radiation gene signature contained both
genes, which did and did not contribute to the tumour/normal
difference in the studied patients (data not shown) [38, 39].
Thus, our study defined the difference in gene expression
related to radiation exposure, and the functional consequences
of this need to be defined. To understand the underlying bio-
logical mechanisms, the genes confirmed by qPCR need to be
examined in independent PTC cases in relation to G2/M cell
cycle arrest. The simultaneous lower expression of CDK1 and
RAD51AP may represent impaired repair of the radiation-
induced DNA damage in ECR patients. The expression of
CDK1 in fibroblasts is reduced in response to radiation [40],
and its suppression is essential for DNA damage-induced G2
arrest [41]. CDK1 is required for efficient 5′ to 3′ resection of
double-strand break ends, and for the recruitment of the
single-stranded DNA-binding complex, RPA and the
RAD51 recombination protein [42]. Decreased RAD51AP,
encoding an enhancer of RAD51, observed in tumours from
ECR patients is consistent with this suggestion, as genetic
ablation of RAD51AP1 leads to enhanced sensitivity to
chromosome aberrations upon DNA damage [43].
RAD5 1AP 1 - d e p l e t e d c e l l s h a v e d e f i c i t s i n
recombination-based repair of a DNA double-strand
break, and exhibit chromatin breaks both spontaneously
and upon DNA-damaging treatment [44].
The simultaneous increase in expression of HDAC11 in
ECR-related PTC creates a link to transcriptional repression
and epigenetic landscaping [45], and can be interpreted as
concordant with both CDK1 and RAD51AP1 decreases as
the latter is regulated by E2F family of transcription factors,
while histone deacetylases interact with RB-E2F to inhibit
gene transcription and are activated by radiation [46]. This
effect may be stronger at the basic higher gene expression
level. The reduced expression of PPME1 may also be related
to the repair of gamma irradiation-induced DNA damage,
which is regulated not only by PP1, but also by PP2A phos-
phatase inhibition [47]. Its protein product, protein phospha-
tase methylesterase 1, is regarded as a key molecule that
Eur J Nucl Med Mol Imaging
sustains the activation of ERK activity in cancer cells via
inhibition of PP2A [47, 48]. The higher expression of this
gene group in thyroid cancers of the ECR group may lead to
the higher activation of MAP cascade downstream of growth
factors, but upstream of RAF and facilitate neoplastic trans-
formation towards PTC [10]. Indeed, 4 of 14 genes known to
modulate PP2A were significantly changed in ECR-related
tumours (Supplementary Table S2). These effects may have
been further enhanced be upregulation of ERBB2 and THRA
(thyroid hormone receptor A) in the ECR group. Recently
THRA-rs939348 was confirmed as a risk factor for DTC
[49], and one may speculate that its increased expression in
ECR tumours is a persistent response to radiation DNA dam-
age which may cooperate with other genes in DTC
development.
Obviously, a number of other potential speculative expla-
nations for the observed gene expression differences could be
presented. It cannot be excluded that cancer induced by a
single dose of radiation shows a difference in cellular homo-
geneity (increased number of multiplied transformed cells and
their desynchronization), kinetics of progression, or even in
the tumour size at diagnosis.
An important study of the molecular biology of thyroid
cancer discussing the results of The Cancer Genome Atlas
(TCGA) has recently been published [28]. The results of the
study indicate the relatively low number of novel genomic
events in PTC compared to the previous knowledge and indi-
cate the presence of subtypes, mainly related to the type of
initiating somatic abnormality. It is an obvious next step to
apply genomic sequencing to analyse in-depth the association
of these subtypes and heterogeneity related to different initi-
ating mutations with the profile of radiation-induced PTC. It is
important to note that the expression of all genes characteristic
of ECR PTCs according to our signature in the PTCs investi-
gated by TCGAwas high.
The important question arises as to whether subtle differ-
ences between the profiles of radiation-induced and sporadic
PTCs have any clinical significance. Probably they do not
reflect profound differences in the underlying disease, but
rather different disease kinetics, cellular composition or –
most interestingly – additional molecular mechanisms operat-
ing in the radiation-induced cancer. The proposed classifier is
not sufficient in itself to distinguish the cancers induced by
low-dose radiation from sporadic cancers, and our results in-
dicate that the effect of radiation is similar in scale to many
other factors influencing the variability of gene expression in
PTC. We did not find any gene expression differences pro-
found enough to influence the clinical course of the disease,
and this is in line with the clinical observations indicating
similar prognosis in post-Chernobyl childhood PTC [3, 50].
However, we interpret the differences observed by us as an
excellent starting point to assess the importance of genes con-
stituting the radiation signature in the pathogenesis of PTC.
In conclusion, we report significant, but subtle, differences
in gene expression in the post-Chernobyl PTC that are asso-
ciated with low-dose radiation exposure. Since the population
exposed to low-dose thyroid radiation (either medical or acci-
dental) is increasing, the study may serve as a basis for further
studies on the susceptibility of the thyroid to low-dose
radiation.
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